NanoViricides Hoping to Fast Track Development of Ebola Cure

The Associated Press reported that NanoViricides Inc. (NYSEMKT:NNVC) is hoping to fast track the development of a cure for Ebola. The company only opened its research and development lab in July.

As quoted in the market news:

U.S. Sen. Richard Blumenthal, D-Conn., recently toured the newly renovated plant. He’s helping the company have its research evaluated by the U.S. Army Medical Research Institute of Infectious Diseases and, once a drug is developed, to move into clinical trials on an emergency basis.

AMRIID evaluates ‘different approaches to cures for various kind of diseases and they focus very intently on Ebola,’ Blumenthal said. ‘We have expedited their attention on the work being done here.’

The company is operating without government financing now, but, Meeta Vyas, chief financial officer, said if the Ebola drug were successful, ‘we would apply for a Department of Defense grant.’

Click here to read the full article from The Associated Press.